4D Molecular Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$15.04 -4.96%
VS HALOHalozyme Therapeutics, Inc.
$107.44 -0.67%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| FDMT | HALO | |
|---|---|---|
| Market Cap | $874.52 million | $12.28 billion |
| Revenue (TTM) | $92.01 million | $1.66 billion |
| Net Income (TTM) | $-179,175,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| FDMT | HALO | |
|---|---|---|
| P/E Ratio | — | 31.42 |
| Price / Book | 2.15 | 85.53 |
| Price / Sales | 9.50 | 7.38 |
FDMT and HALO split the valuation factors evenly.
Profitability
| FDMT | HALO | |
|---|---|---|
| Net Margin | -194.74% | 24.86% |
| Return on Equity | -43.95% | 288.13% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| FDMT | HALO | |
|---|---|---|
| Short Interest | 0.41% | 9.79% |
FDMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: FDMT overview, FDMT financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.